Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-23

Novavax (NVAX)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$8,856,015
John Jacobs total, FY2025
60th
CEO pay percentile vs peers
52:1
CEO-to-median pay ratio
50.65%
Say-on-pay support, latest vote
Companies that benchmark against NVAX
3 companies name NVAX as a compensation peer

Each company listed discloses NVAX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NVAX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
John Jacobs$792,917$0$3,545,435$3,763,292$640,331$0$114,040$8,856,015
President and Chief Executive Officer
Elaine O'Hara561,08001,330,0301,411,235288,143097,7883,688,276
Executive Vice President, Chief Strategy Officer
James Kelly572,88601,019,1651,082,782297,362014,0332,986,228
Executive Vice President, Chief Financial Officer and Treasurer
Mark Casey577,8310885,375940,823289,6600116,7642,810,453
Executive Vice President, Chief Legal Officer and Corporate Secretary
Ruxandra Draghia-Akli600,0000629,600668,040290,2500115,4902,303,380
Former Executive Vice President, Head of Research & Development
John Trizzino310,0160368,624209,72400821,5861,709,950
Former President and Chief Operating Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
John Jacobs$8,856,015$5,087,461$7,301,009+3,768,554
Elaine O'Hara3,688,2761,638,116+2,050,160
James Kelly2,986,2281,829,4891,503,833+1,156,739
Mark Casey2,810,4531,062,3341,534,587+1,748,119
Ruxandra Draghia-Akli2,303,380
John Trizzino1,709,9501,633,4171,877,883+76,533

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Rachel K. KingDirector2026-06-18A21,270$0$0Derivative, Class A CommonForm 4 ↗
Margaret G. McGlynnDirector2026-06-18D18,88000Derivative, Class A CommonForm 4 ↗
David MottDirector2026-06-18D18,88000Derivative, Class A CommonForm 4 ↗
Richard J. RodgersDirector2026-06-18D18,88000Derivative, Class A CommonForm 4 ↗
Richard J. RodgersDirector2026-06-18A14,18000Derivative, Class A CommonForm 4 ↗
Rachel K. KingDirector2026-06-18A14,18000Derivative, Class A CommonForm 4 ↗
Richard DouglasDirector2026-06-18A21,27000Derivative, Class A CommonForm 4 ↗
Margaret G. McGlynnDirector2026-06-18A21,27000Derivative, Class A CommonForm 4 ↗
David MottDirector2026-06-18A14,18000Derivative, Class A CommonForm 4 ↗
Gregg H. AltonDirector2026-06-18A14,18000Derivative, Class A CommonForm 4 ↗
John W. ShiverDirector2026-06-18A21,27000Derivative, Class A CommonForm 4 ↗
John W. ShiverDirector2026-06-18A14,18000Derivative, Class A CommonForm 4 ↗
Richard J. RodgersDirector2026-06-18A21,27000Derivative, Class A CommonForm 4 ↗
Rachel K. KingDirector2026-06-18A18,880CommonForm 4 ↗
Richard DouglasDirector2026-06-18A14,18000Derivative, Class A CommonForm 4 ↗
Richard DouglasDirector2026-06-18D18,88000Derivative, Class A CommonForm 4 ↗
Margaret G. McGlynnDirector2026-06-18A14,18000Derivative, Class A CommonForm 4 ↗
David MottDirector2026-06-18A18,880CommonForm 4 ↗
David MottDirector2026-06-18A21,27000Derivative, Class A CommonForm 4 ↗
Gregg H. AltonDirector2026-06-18A18,880CommonForm 4 ↗
Gregg H. AltonDirector2026-06-18A21,27000Derivative, Class A CommonForm 4 ↗
Gregg H. AltonDirector2026-06-18D18,88000Derivative, Class A CommonForm 4 ↗
Richard J. RodgersDirector2026-06-18A18,880CommonForm 4 ↗
Richard DouglasDirector2026-06-18A18,880CommonForm 4 ↗
Charles W. NewtonDirector2026-06-18A14,18000Derivative, Class A CommonForm 4 ↗
Margaret G. McGlynnDirector2026-06-18A18,880CommonForm 4 ↗
Rachel K. KingDirector2026-06-18D18,88000Derivative, Class A CommonForm 4 ↗
Charles W. NewtonDirector2026-06-18A21,27000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Mark CaseyRSU2025-03-03112,500$885,375
Ruxandra Draghia-AkliRSU2025-03-0380,000629,600
John JacobsOPTION2025-03-03676,0003,763,292
Ruxandra Draghia-AkliOPTION2025-03-03120,000668,040
Elaine O HaraOPTION2025-03-03253,5001,411,235
John JacobsRSU2025-03-03450,5003,545,435
James KellyRSU2025-03-03129,5001,019,165
James KellyOPTION2025-03-03194,5001,082,782
Mark CaseyOPTION2025-03-03169,000940,823
Elaine O HaraRSU2025-03-03169,0001,330,030
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Mark Casey$885,375$0$940,8230.0%
Ruxandra Draghia-Akli629,6000668,0400.0%
John Jacobs3,545,43503,763,2920.0%
Elaine O Hara1,330,03001,411,2350.0%
James Kelly1,019,16501,082,7820.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Elaine O'HaraOption72,3485.57
James KellyOption1,29777.77
John TrizzinoOption46,7779.01
James KellyRSU12,22382,139
Ruxandra Draghia-AkliRSU28,513191,607
Mark CaseyRSU112,500756,000
James KellyOption21,2196.86
Elaine O'HaraRSU80,000537,600
Elaine O'HaraRSU19,600131,712
James KellyRSU129,500870,240
Mark CaseyRSU41,899281,561
John JacobsRSU450,5003,027,360
James KellyOption194,5007.87
John JacobsOption676,0007.87
John TrizzinoOption1,29777.77
Mark CaseyOption169,0007.87
Ruxandra Draghia-AkliRSU80,000537,600
Elaine O'HaraRSU169,0001,135,680
John JacobsRSU83,197559,084
James KellyRSU117,333788,478
John JacobsOption281,2515.39
James KellyOption13,2356.97
Elaine O'HaraOption253,5007.87
Ruxandra Draghia-AkliOption120,0007.87
John JacobsRSU166,6661,119,996
John TrizzinoRSU96,000645,120
John TrizzinoRSU28,890194,141
Mark CaseyRSU8,00053,760
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program is designed to attract and retain appropriately qualified and industry experienced executives capable of leading the company to the consistent delivery of our mission, vision, and goals. We maintain a compensation philosophy that rewards executives for Company performance tied to attainment of key performance goals.

CEO STI target (% of salary)85%
CEO LTI target (% of salary)
Independent consultantPearl Meyer
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1835,779,46134,858,658737,89750.65%Passed
20252025-06-2041,390,65115,830,308530,26272.33%Passed
20242024-06-1324,187,6728,695,35711,007,35073.56%Passed
20232023-07-1115,695,5783,030,052538,43583.82%Passed
20222022-06-1619,618,7986,574,169243,53974.9%Passed
20212021-06-1731,917,6688,631,639340,26378.71%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1850.65%a
20252025-06-2072.33%b
20242024-06-1373.56%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as shares voting on this matter and accordingly will have no effect on the approval of this Proposal 3.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)52 : 1
CEO total compensation$8,856,015
Median employee compensation$169,449
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
John W. Shiver, Ph.DIndependent · Compensation · Newly elected$59,987$195,011$261,547$0$516,545
Charles W. NewtonIndependent · Audit · Newly elected45,982190,495255,4720491,949
Margaret G. McGlynn, R. PhIndependent119,187121,021162,0700402,278
Richard J. RodgersIndependent · Audit (Chair) · Compensation92,358121,021162,0700375,449
David MottIndependent · Board Chair · Compensation (Chair)82,500121,021162,0700365,591
Richard H. Douglas, Ph.DIndependent · Audit81,371121,021162,0700364,462
Gregg H. Alton, J.DIndependent · Audit · Nominating/Governance · Capital Allocation72,000121,021162,0700355,091
Rachel K. KingIndependent · Compensation70,000121,021162,0700353,091
James F. Young, Ph.DIndependent · Departed during FY58,750058,750
John C. JacobsEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$55,000
Annual equity retainer$283,091
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$682,135
Equity awards (grant-date value)$1,111,632
All other compensation$0
Total cost of the board$1,793,767

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Novavax names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Novavax.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Halozyme Therapeutics, Inc.2025Helen Torley$1,000,000$19,350,145$1,650,014$1,147,500$23,166,223
2Insmed Incorporated2025William Lewis854,5502,999,9409,000,0331,495,46314,467,393
3Novavax2025John Jacobs792,9173,545,4353,763,292640,3318,856,015
4Amneal Pharmaceuticals Inc.2025Chirag Patel800,0006,974,9950848,0008,691,745
5Bicycle2025Kevin Lee862,3391,724,8002,961,297543,6426,341,473
6Beam Therapeutics Inc.2025John Evans755,0001,513,5752,876,754662,5135,818,525
Organogenesis Holdings, Inc.not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Novavax95%Options 50 · RSU 50not disclosedPearl Meyer
Amneal Pharmaceuticals Inc.106%PSU 65 · RSU 35NoMeridian
Beam Therapeutics Inc.135%Options 66 · RSU 34not disclosedPay Governance LLC
Bicycle97%not disclosednot disclosednot disclosed
Halozyme Therapeutics, Inc.127.5%PSU 50 · RSU 35 · Option 15NoF.W. Cook & Co., Inc.
Insmed Incorporated175%Options 75 · RSU 25NoWillis Towers Watson (WTW)
Organogenesis Holdings, Inc.not disclosednot disclosednot disclosednot disclosed

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, John JacobsDEF 14A2026-04-270001628280-26-027328Section “Summary Compensation Table”. As printed: 8,856,015. Filing ↗machine: t197 · r2 · c8 · span 944385–944394
2Section 01, Elaine O'HaraDEF 14A2026-04-270001628280-26-027328Section “SUMMARY COMPENSATION TABLE”. As printed: 3,688,276. Filing ↗machine: r10 · c24 · span 959901–959910
3Section 01, James KellyDEF 14A2026-04-270001628280-26-027328Section “SUMMARY COMPENSATION TABLE”. As printed: 2,986,228. Filing ↗machine: r6 · c24 · span 952171–952180
4Section 01, Mark CaseyDEF 14A2026-04-270001628280-26-027328Section “SUMMARY COMPENSATION TABLE”. As printed: 2,810,453. Filing ↗machine: r13 · c24 · span 965741–965750
5Section 01, Ruxandra Draghia-AkliDEF 14A2026-04-270001628280-26-027328Section “SUMMARY COMPENSATION TABLE”. As printed: 2,303,380. Filing ↗machine: r21 · c24 · span 982057–982066
6Section 01, John TrizzinoDEF 14A2026-04-270001628280-26-027328Section “SUMMARY COMPENSATION TABLE”. As printed: 1,709,950. Filing ↗machine: r17 · c24 · span 973879–973888
7Section 03, Mark Casey RSUDEF 14A2026-04-270001628280-26-027328Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r5 · c1 · span 882015–882022
8Section 03, Ruxandra Draghia-Akli RSUDEF 14A2026-04-270001628280-26-027328Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r6 · c1 · span 882597–882603
9Section 03, John Jacobs OPTIONDEF 14A2026-04-270001628280-26-027328Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r2 · c1 · span 875933–875940
10Section 03, Ruxandra Draghia-Akli OPTIONDEF 14A2026-04-270001628280-26-027328Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r6 · c1 · span 877991–877998
11Section 03, Elaine O Hara OPTIONDEF 14A2026-04-270001628280-26-027328Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r4 · c1 · span 876906–876913
12Section 03, John Jacobs RSUDEF 14A2026-04-270001628280-26-027328Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r2 · c1 · span 880539–880546
13Section 03, James Kelly RSUDEF 14A2026-04-270001628280-26-027328Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r3 · c1 · span 881026–881033
14Section 03, James Kelly OPTIONDEF 14A2026-04-270001628280-26-027328Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r3 · c1 · span 876420–876427
15Section 03, Mark Casey OPTIONDEF 14A2026-04-270001628280-26-027328Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r5 · c1 · span 877409–877416
16Section 03, Elaine O Hara RSUDEF 14A2026-04-270001628280-26-027328Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t200 · r13 · c8 · span 1012633–1012642
17Section 07, pay ratioDEF 14A2026-04-270001628280-26-027328Section “CEO Pay Ratio”. As printed: 52 : 1. Filing ↗machine: t230 · r3 · c1 · span 1235866–1235873
18Section 08, John W. Shiver, Ph.DDEF 14A2026-04-270001628280-26-027328Section “Director Compensation”. As printed: 516,545. Filing ↗machine: t106 · r9 · c4 · span 592136–592143
19Section 08, Charles W. NewtonDEF 14A2026-04-270001628280-26-027328Section “Director Compensation”. As printed: 491,949. Filing ↗machine: t106 · r7 · c4 · span 589555–589562
20Section 08, Margaret G. McGlynn, R. PhDEF 14A2026-04-270001628280-26-027328Section “Director Compensation”. As printed: 402,278. Filing ↗machine: t106 · r5 · c4 · span 586986–586993
21Section 08, Richard J. RodgersDEF 14A2026-04-270001628280-26-027328Section “Director Compensation”. As printed: 375,449. Filing ↗machine: t106 · r8 · c4 · span 590752–590759
22Section 08, David MottDEF 14A2026-04-270001628280-26-027328Section “Director Compensation”. As printed: 365,591. Filing ↗machine: t106 · r6 · c4 · span 588175–588182
23Section 08, Richard H. Douglas, Ph.DDEF 14A2026-04-270001628280-26-027328Section “Director Compensation”. As printed: 364,462. Filing ↗machine: t106 · r3 · c4 · span 584586–584593
24Section 08, Gregg H. Alton, J.DDEF 14A2026-04-270001628280-26-027328Section “Director Compensation”. As printed: 355,091. Filing ↗machine: t106 · r2 · c4 · span 583371–583378
25Section 08, Rachel K. KingDEF 14A2026-04-270001628280-26-027328Section “Director Compensation”. As printed: 353,091. Filing ↗machine: t106 · r4 · c4 · span 585779–585786
26Section 08, James F. Young, Ph.DDEF 14A2026-04-270001628280-26-027328Section “Director Compensation”. As printed: 58,750. Filing ↗machine: t106 · r10 · c1 · span 592899–592905
27Section 08, John C. JacobsDEF 14A2026-04-270001628280-26-027328Section “Director Compensation”. As printed: 0. Filing ↗
28Section 02, Rachel K. King 2026-06-18Form 42026-06-230001104659-26-076928Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Margaret G. McGlynn 2026-06-18Form 42026-06-230001104659-26-076926Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, David Mott 2026-06-18Form 42026-06-230001104659-26-076925Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Richard J. Rodgers 2026-06-18Form 42026-06-230001104659-26-076930Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Richard J. Rodgers 2026-06-18Form 42026-06-230001104659-26-076930Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Rachel K. King 2026-06-18Form 42026-06-230001104659-26-076928Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Richard Douglas 2026-06-18Form 42026-06-230001104659-26-076927Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Margaret G. McGlynn 2026-06-18Form 42026-06-230001104659-26-076926Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, David Mott 2026-06-18Form 42026-06-230001104659-26-076925Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Gregg H. Alton 2026-06-18Form 42026-06-230001104659-26-076924Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, John W. Shiver 2026-06-18Form 42026-06-230001104659-26-076923Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, John W. Shiver 2026-06-18Form 42026-06-230001104659-26-076923Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Richard J. Rodgers 2026-06-18Form 42026-06-230001104659-26-076930Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Rachel K. King 2026-06-18Form 42026-06-230001104659-26-076928Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Richard Douglas 2026-06-18Form 42026-06-230001104659-26-076927Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Richard Douglas 2026-06-18Form 42026-06-230001104659-26-076927Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Margaret G. McGlynn 2026-06-18Form 42026-06-230001104659-26-076926Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, David Mott 2026-06-18Form 42026-06-230001104659-26-076925Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, David Mott 2026-06-18Form 42026-06-230001104659-26-076925Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Gregg H. Alton 2026-06-18Form 42026-06-230001104659-26-076924Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Gregg H. Alton 2026-06-18Form 42026-06-230001104659-26-076924Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Gregg H. Alton 2026-06-18Form 42026-06-230001104659-26-076924Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Richard J. Rodgers 2026-06-18Form 42026-06-230001104659-26-076930Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Richard Douglas 2026-06-18Form 42026-06-230001104659-26-076927Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Charles W. Newton 2026-06-18Form 42026-06-230001104659-26-076922Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Margaret G. McGlynn 2026-06-18Form 42026-06-230001104659-26-076926Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Rachel K. King 2026-06-18Form 42026-06-230001104659-26-076928Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Charles W. Newton 2026-06-18Form 42026-06-230001104659-26-076922Insider equity transaction reported since the proxy statement. Filing ↗
56Section 06, 2026 voteForm 8-K2026-06-230001104659-26-076648Item 5.07 · say-on-pay result. As reported: 50.65% (votes for as printed: 35,779,461). Filing ↗
57Section 06, 2025 voteForm 8-K2025-06-240001104659-25-061874Item 5.07 · say-on-pay result. As reported: 72.33% (votes for as printed: 41,390,651). Filing ↗
58Section 06, 2024 voteForm 8-K2024-06-140001104659-24-071735Item 5.07 · say-on-pay result. As reported: 73.56% (votes for as printed: 24,187,672). Filing ↗
59Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
60Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
61Section 09b board cost (computed)ComputedcomputedCash 682,135 + equity 1,111,632 + all other 0 = 1,793,767, summed across the director compensation table rows.machine: formula: Σ = 1,793,767
62Halozyme Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-03-230001159036-26-000041CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292
63Insmed Incorporated, Section 10b CEO totalDEF 14A2026-04-010001104506-26-000022CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563
64Novavax (subject), Section 10b CEO totalDEF 14A2026-04-270001628280-26-027328CEO total compensation as printed in Novavax's own proxy. As printed: 8,856,015. Filing ↗machine: t197 · r2 · c8 · span 944385–944394
65Amneal Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-03-250001308179-26-000143CEO total compensation as printed in Amneal Pharmaceuticals Inc.'s own proxy. As printed: 8,691,745. Filing ↗machine: r4 · c16 · span 470587–470596
66Bicycle, Section 10b CEO totalDEF 14A2026-04-220001104659-26-046806CEO total compensation as printed in Bicycle's own proxy. As printed: 6,341,473. Filing ↗machine: t83 · r5 · c14 · span 491024–491033
67Beam Therapeutics Inc., Section 10b CEO totalDEF 14A2026-04-170001193125-26-161512CEO total compensation as printed in Beam Therapeutics Inc.'s own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178
68Section 10a, Insmed Incorporated reciprocityDEF 14A0001104506-26-000022Insmed Incorporated's most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗
69Section 10a, Halozyme Therapeutics, Inc. reciprocityDEF 14A0001159036-26-000041Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗
70Section 10a, Beam Therapeutics Inc. reciprocityDEF 14A0001193125-26-161512Beam Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗